Kaohsiung Medical University

National Yang Ming Chiao Tung University

Ming-Lung Yu

Wan-Long Chuang

Chia-Yen Dai

Jee-Fu Huang

Jinn-Moon Yang

Edward Hsi

Yun-Ti Chen

Shey-Cherng Tzou

Yu-Min Ko

Ming-Ying Lu

Hsiao-Chen Huang

Jung-Yu Lee

Wen-Wen Chou

Disclosed herein is a method for alleviating a chronic liver disease, comprising administrating to a subject in need thereof a pharmaceutical composition containing rosoxacin.

Method for alleviating chronic liver disease using Rosoxacin

A method for detecting whether glucose metabolism is abnormal comprises: detecting GPx2 gene expression, GPx2 protein expression or the activity of GPx2 protein in a test body, and making comparisons with GPx2 expression amount of a normal individual, when the GPx2 expression of the individual is significantly lower than that of the normal individual, indicating that the carbohydrate metabolism of the individual is in an abnormal state. Applications of GPx2 in the preparation of a medical composition for the treatment and prevention of type II diabetes.

Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor

The present invention provides a method for predicting treatment efficacy of peginterferon plus ribavirin treatment in a subject suffering from chronic hepatitis C comprising: (a) measuring gene expression levels of genes comprising RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3 and DDX60 of a blood sample from the subject after one week of the peginterferon plus ribavirin treatment; and (b) calculating a gene score according to cumulative fold change of the gene expression levels, when the gene score is equal to or higher than a cut-off value, the method predicts successful treatment of chronic hepatitis C with the peginterferon plus ribavirin treatment for the subject.

Method for predicting treatment efficacy of peginterferon plus ribavirin treatment in a subject suffering from hepatitis C

A method for evaluating the therapeutic efficacy of interferon (IFN)/ribavirin (RBV) for hepatitis C is disclosed. The method includes the steps of providing a specimen; mixing the specimen, a primer of a miRNA Let-7g and a poly-chain reaction (PCR) reagent together; and evaluating the efficacy of IFN/RBV on inhibiting a hepatitis C virus according to the expressing level of the miRNA Let-7g in the specimen detected by the PCR reagent.

Use of Let-7g to down regulate NS5B gene, core protein and viral load of hepatitis C virus

Growing community of inventors

Kaohsiung, Taiwan

Ming-Lung Yu